Novartis shares fall as Entresto sales weaken

Pharmaphorum

Novartis is showing the effects of its patent cliff more strongly, with generic competition hitting sales and profits in the first quarter of 2026.

pharminent April 28, 2026 (Last updated: April 28, 2026)

Pharmaphorum

Novartis is showing the effects of its patent cliff more strongly, with generic competition hitting sales and profits in the first quarter of 2026.

Related Stories